Grail Inc (GRAL) Stock Price, Quote & News

Company Profile

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing,...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 833 694 2553

Website: grail.com

Address:

1525 O’Brien Drive, Menlo Park, United States

MoneyGroupLLC Dec. 14 at 6:14 AM

Enter: $GRAL Calls Strike Price: $95 Expiry Date: JAN 16 2026 Buy in Price: $7.90 - $9.00 Sell Price: $12.32 Profit : +56% (Turn every $1 into $1.56) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

MoneyGroupLLC Dec. 12 at 4:03 AM

Enter: $GRAL Calls Strike Price: $95 Expiry Date: JAN 16 2026 Buy in Price: $12.00 - $12.70 Sell Price: $23.76 Profit : +98% (Turn every $1 into $1.98) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

PrivateProfiteersAnalyst Dec. 12 at 12:48 AM

$GRAL Actionable Trade Alert: Market Context: $GRAL is currently trading at $94.41, showing a healthy RSI of 56.98, indicating bullish momentum without being overbought. The price is above the 30-day MA of $92.54 and significantly above the 50-day MA of $86.09, suggesting a positive trend. Directional Bias: The recent price action is within the 60-day high of $115.76 and low of $38.89, indicating potential for upward movement. The ATR of 7.73 suggests volatility, allowing for significant price swings. Trade Plan: - Suggested Entry: $94.50 - Stop Loss: $88.00 (6.6% risk) - Take Profit Targets: 1. TP1: $101.00 (7% ROI) 2. TP2: $110.00 (16.5% ROI) 3. TP3: $110.00 (17.5% ROI) With the potential for a 17% ROI on TP3, this trade aligns well with current market conditions. Monitor closely and adjust stops as necessary. https://privateprofiteers.com

0 · Reply

MoneyGroupLLC Dec. 11 at 9:38 AM

Enter: $GRAL Calls Strike Price: $95 Expiry Date: JAN 16 2026 Buy in Price: $12.00 - $12.00 Sell Price: $18.72 Profit : +56% (Turn every $1 into $1.56) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

WAJeff Dec. 10 at 8:35 PM

$GRAL Quick flip from 92.51 to 95 this morning

0 · Reply

Arcides Dec. 10 at 2:44 PM

$GRAL This is begining to look like a failed breakout...good breakouts have inmediate follow through, and lets say it had already made a monster move from 30 to 115.

0 · Reply

BillionerOfKing Dec. 10 at 11:40 AM

$GRAL Current Stock Price: $97.42 Contracts to trade: $95 GRAL Dec 19 2025 Call Entry: $6.75 Exit: $12.08 ROI: 79% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

PrivateProfiteersAnalyst Dec. 10 at 4:51 AM

$GRAL Trade Alert: Market Context: Currently, $GRAL is trading at $97.46, showing bullish momentum as indicated by an RSI of 61.67, suggesting it is not overbought yet. The price is above both the 30-day MA of $91.94 and the 50-day MA of $84.73, reinforcing a positive directional bias. Directional Bias: The recent high of $115.76 indicates strong resistance above, while the low of $36.98 shows significant support. The current price is well-positioned for potential upside. Trade Plan: - Suggested Entry: $97.50 - Stop Loss: $90.00 - Take Profit Targets: 1. $105.00 (7.5% ROI) 2. $112.50 (15.4% ROI) 3. $114.50 (17.5% ROI) This setup allows for a favorable risk-to-reward ratio while aiming for over 17% ROI on the final target. Stay informed and trade wisely. https://privateprofiteers.com

0 · Reply

Ps0206 Dec. 10 at 4:40 AM

$GRAL I said here even for biotech stocks that have risen a lot, insider selling is not uncommon (NTRA, GH, EXAS). Insider selling not something positive, but no point to be too concerned

0 · Reply

MoneyGroupLLC Dec. 10 at 1:18 AM

Enter: $GRAL Calls Strike Price: $100 Expiry Date: JAN 16 2026 Buy in Price: $11.50 - $13.49 Sell Price: $26.71 Profit : +98% (Turn every $1 into $1.98) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Here's Why Grail Soared, Again, in November

Dec 1, 2025, 4:01 PM EST - 12 days ago

GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Nov 24, 2025, 9:11 AM EST - 19 days ago

Deutsche Bank may have just set a holy-grail goal for the S&P 500

DB IVV SPXL SPY SSO UPRO VOO

Nov 18, 2025, 4:02 PM EST - 25 days ago

GRAIL to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 17, 2025, 7:30 PM EST - 26 days ago

Why Grail Stock Zoomed Nearly 7% Higher on Monday

Nov 13, 2025, 12:58 PM EST - 4 weeks ago

Grail Q3 Earnings: Massive Stock Gains, Mediocre Performance - I'm Still Not Sold

Nov 12, 2025, 6:21 PM EST - 4 weeks ago

GRAIL, Inc. (GRAL) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 4:02 PM EST - 4 weeks ago

GRAIL Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 6:00 AM EST - 5 weeks ago

Here's Why Grail Stock Exploded Higher by 55% in October

Nov 4, 2025, 4:02 PM EST - 5 weeks ago

GRAIL to Present at 7th Annual Wolfe Research Healthcare Conference

Nov 4, 2025, 3:15 PM EST - 5 weeks ago

Top Biotech Stocks Riding The Rally

CTMX GRFS INCY

Oct 29, 2025, 4:02 PM EDT - 6 weeks ago

GRAIL to Announce Third Quarter 2025 Financial Results

Oct 27, 2025, 7:00 AM EDT - 6 weeks ago

GRAIL: Buy Τhe Test That Could Redefine Cancer Screening

Oct 23, 2025, 9:55 AM EDT - 7 weeks ago

Grail Stock Is Up 80% Over the Past Month. Here's Why.

Oct 22, 2025, 8:05 PM EDT - 7 weeks ago

Odds of these speculative stocks making you money seems very slim, says Jim Cramer

ASTS TGEN TMQ AUR RGTI

Oct 21, 2025, 12:19 PM EDT - 7 weeks ago

Grail's CEO Sells 7,200 Shares for nearly $500,000

Oct 20, 2025, 5:05 PM EDT - 7 weeks ago

GRAIL, Inc. (GRAL) Discusses PATHFINDER 2 Study Results and Clinical Program in Multi-Cancer Early Detection Transcript

Oct 20, 2025, 6:30 AM EDT - 7 weeks ago

GRAIL, Inc. Announces $325.0 Million Private Placement Financing

Oct 20, 2025, 6:00 AM EDT - 7 weeks ago

GRAIL and University of Oxford to Present Long-Term Data From the SYMPLIFY Study Evaluating the Galleri® Multi-Cancer Early Detection Test in Symptomatic Individuals at the Early Detection of Cancer Conference (EDCC)

Oct 17, 2025, 6:08 PM EDT - 2 months ago

GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings

Oct 17, 2025, 9:55 AM EDT - 2 months ago

What's Happening With GRAIL Stock?

Oct 16, 2025, 6:52 PM EDT - 2 months ago

Why Grail Stock Soared 14% Higher on Thursday

Oct 16, 2025, 8:22 AM EDT - 2 months ago

Samsung and GRAIL Announce Strategic Collaboration to Bring GRAIL's Galleri® Multi-Cancer Early Detection Test to Asia

Sep 30, 2025, 12:17 PM EDT - 2 months ago

Grail: A Speculative Buy

Sep 26, 2025, 12:46 PM EDT - 2 months ago

This Cancer Detection Pioneer Is Worth a Look

Sep 23, 2025, 9:01 AM EDT - 2 months ago

GRAIL to Present New Galleri® Data From More Than 32,000 Participants Across the PATHFINDER 2, SYMPLIFY and REFLECTION Studies at ESMO Congress 2025 and EDCC

Sep 19, 2025, 8:47 AM EDT - 3 months ago

Sun World International and Pairwise Launch Strategic Partnership to Develop a Holy Grail of Produce – the Pitless Cherry

Sep 10, 2025, 4:02 PM EDT - 3 months ago

GRAIL to Present at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

Sep 9, 2025, 5:31 PM EDT - 3 months ago

GRAIL, Inc. (GRAL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 28, 2025, 6:20 AM EDT - 3 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX DHR ILMN IONS MRNA RGEN

Aug 26, 2025, 4:02 PM EDT - 3 months ago

GRAIL to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 12, 2025, 7:13 PM EDT - 4 months ago

GRAIL, Inc. (GRAL) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:02 PM EDT - 4 months ago

GRAIL Reports Second Quarter 2025 Financial Results

Jul 30, 2025, 4:02 PM EDT - 4 months ago

GRAIL to Present at Canaccord Genuity 45th Annual Growth Conference

Jul 29, 2025, 4:02 PM EDT - 4 months ago

GRAIL to Announce Second Quarter 2025 Financial Results

Jun 23, 2025, 5:30 AM EDT - 6 months ago

The Holy Grail of Automation: Now a Robot Can Unload a Truck

Jun 18, 2025, 12:43 PM EDT - 6 months ago

Grail Shares Jump on Promising Results for Galleri Study

Jun 18, 2025, 9:01 AM EDT - 6 months ago

GRAIL Announces Positive Top-Line Results From The Galleri® PATHFINDER 2 Registrational Study

May 21, 2025, 4:05 PM EDT - 7 months ago

GRAIL to Present at Jefferies Global Healthcare Conference 2025

May 14, 2025, 8:13 AM EDT - 7 months ago

Alcon, American Eagle, GRAIL And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

ALC

May 13, 2025, 7:16 PM EDT - 7 months ago

GRAIL, Inc. (GRAL) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:01 PM EDT - 7 months ago

GRAIL Reports First Quarter 2025 Financial Results

May 12, 2025, 4:01 PM EDT - 7 months ago

GRAIL and athenahealth Team Up to Offer Healthcare Providers Streamlined Ordering of GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test

Apr 29, 2025, 4:01 PM EDT - 8 months ago

GRAIL to Announce First Quarter 2025 Financial Results

Apr 22, 2025, 4:01 PM EDT - 8 months ago

GRAIL to Present New Data on Galleri® and its Methylation Platform at American Association for Cancer Research (AACR) Annual Meeting

Apr 21, 2025, 4:47 PM EDT - 8 months ago

This Cancer Test Could Become Routine—and a Big Seller, Says Analyst

Apr 12, 2025, 9:32 AM EDT - 8 months ago

GRAIL's Galleri Progresses While Back In Accumulation Levels

Apr 8, 2025, 9:49 AM EDT - 8 months ago

How Does GRAIL Benefit From The Proposed MCED Legislation?

Feb 25, 2025, 9:00 AM EST - 10 months ago

GRAIL Partners With Actress Kate Walsh for Generation Possible to Raise Awareness of Multi-Cancer Early Detection Testing

Feb 21, 2025, 9:00 AM EST - 10 months ago

GRAIL to Present at TD Cowen 45th Annual Health Care Conference

MoneyGroupLLC Dec. 14 at 6:14 AM

0 · Reply

MoneyGroupLLC Dec. 12 at 4:03 AM

0 · Reply

PrivateProfiteersAnalyst Dec. 12 at 12:48 AM

0 · Reply

MoneyGroupLLC Dec. 11 at 9:38 AM

0 · Reply

WAJeff Dec. 10 at 8:35 PM

$GRAL Quick flip from 92.51 to 95 this morning

0 · Reply

Arcides Dec. 10 at 2:44 PM

$GRAL This is begining to look like a failed breakout...good breakouts have inmediate follow through, and lets say it had already made a monster move from 30 to 115.

0 · Reply

BillionerOfKing Dec. 10 at 11:40 AM

0 · Reply

PrivateProfiteersAnalyst Dec. 10 at 4:51 AM

0 · Reply

Ps0206 Dec. 10 at 4:40 AM

$GRAL I said here even for biotech stocks that have risen a lot, insider selling is not uncommon (NTRA, GH, EXAS). Insider selling not something positive, but no point to be too concerned

0 · Reply

MoneyGroupLLC Dec. 10 at 1:18 AM

0 · Reply

CapitalGains007 Dec. 10 at 12:31 AM

$GRAL the float is irrelevant, it’s the signaling that’s important.

0 · Reply

SimpleWinningSetups Dec. 9 at 10:22 PM

Hedge Alert Live - Protect Your Portfolio Contract: $GRAL $95.00 Put · DEC 19, 2025 Exp Entry Price: $5.39 - $5.40 Exit Price Target: $11.00 Profit Margin: +104% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Ps0206 Dec. 9 at 2:18 PM

$GRAL Insider sales are worth watching. But Bob/Josh/Aaron sold ~78k shares on 3 Dec – <0.2% of the float – after a 4× move in the stock, and they still hold ~1.3m shares combined (~US100M+ at ~100). A lot of their comp is in stock/RSUs, so periodic sales for tax + diversification are normal. Other high-growth biotechs (NTRA, GH, EXAS) have seen similar or heavier insider selling this year without it signalling “imminent bad news” (Bob/Josh/Aaron also sold significantly before the big rise during Oct-Nov 2025, so I’m not worrying too much) Everyone has their own risk view

0 · Reply

PrivateProfiteersAnalyst Dec. 9 at 12:39 AM

$GRAL Actionable Trade Alert: Market Context: $GRAL is currently trading at $100.33, showing a strong upward momentum with an RSI of 61.12, indicating bullish sentiment but approaching overbought territory. The price is well above the 30-day MA of 91.55 and the 50-day MA of 83.96, suggesting a strong trend. Directional Bias: The recent high of $115.76 indicates potential upside, while the low of $36.98 provides a solid support base. The ATR of 9.0 suggests volatility, allowing for significant price movements. Trade Plan: - Suggested Entry: $100.50 - Stop Loss: $93.00 (7.5% below entry) - Take Profit Targets: 1. $107.00 (6.5% gain) 2. $115.00 (14.4% gain) 3. $117.50 (17.1% gain) With a target of $117.50, this trade offers a potential ROI of over 17%. Monitor RSI and price action for adjustments. https://privateprofiteers.com

0 · Reply

MoneyGroupLLC Dec. 9 at 12:02 AM

Enter: $GRAL Calls Strike Price: $105 Expiry Date: JAN 16 2026 Buy in Price: $10.30 - $12.20 Sell Price: $20.91 Profit : +103% (Turn every $1 into $2.03) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

HCEarwicker Dec. 8 at 6:52 PM

$GRAL NY Times 12/8/25 — "Cancer-Detecting Blood Tests Are on the Rise. Do They Work?" (gift article) — https://www.nytimes.com/2025/12/02/well/cancer-detecting-blood-tests-are-on-the-rise-do-they-work.html?unlocked_article_code=1.7E8.vHcn.nNfgZj5JgQls&smid=url-share

0 · Reply

CapitalGains007 Dec. 8 at 5:37 PM

$GRAL your boys are selling, Josh, Bob, and Aaron coordinated cash out!!

0 · Reply

CapitalGains007 Dec. 7 at 9:39 PM

$GRAL these guys know…Bob selling, Josh selling, now Aaron? All multi-million dollar sales, either they are about to get diluted again, OR, they know bad news may be delaying timelines for fda submission. Your top 3 guys all off loading at $100/share + all multimillion all within days….

0 · Reply

MoneyGroupLLC Dec. 7 at 8:28 AM

Enter: $GRAL Calls Strike Price: $105 Expiry Date: JAN 16 2026 Buy in Price: $10.30 - $11.50 Sell Price: $15.66 Profit : +52% (Turn every $1 into $1.52) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

PrivateProfiteersAnalyst Dec. 6 at 3:38 AM

Actionable Trade Alert for $GRAL: Market Context: $GRAL is currently trading at $104.71, showing strong momentum with an RSI of 64.59, indicating it is nearing overbought territory. However, the price is well above the MA30 (90.57) and MA50 (81.9), suggesting bullish sentiment in the short to mid-term. Directional Bias: The bullish trend is supported by the recent price action, which is approaching the 60D high of $115.76. The distance from the 60D low of $35.43 indicates significant upward potential. Trade Plan: - Suggested Entry: $104.71 - Stop Loss: $95.00 (approx. 9.5% below entry) - Take Profit Targets: 1. $110.00 (5% gain) 2. $120.00 (14.6% gain) 3. $123.00 (17.5% gain) With a potential ROI of over 17% on the third target, this trade offers a favorable risk-reward ratio. Monitor the RSI and price action closely for any signs of reversal. https://privateprofiteers.com

0 · Reply

PrivateProfiteersAnalyst Dec. 5 at 11:14 PM

0 · Reply

MarcoFla99 Dec. 5 at 9:27 PM

$GRAL Grail Insider Sold Shares Worth $2,478,818, According to a Recent SEC Filing MT NEWSWIRES 4:22 PM ET 12/5/2025 04:22 PM EST, 12/05/2025 (MT Newswires) -- Aaron Freidin, Chief Financial Officer, on December 03, 2025, sold 25,000 shares in Grail (GRAL) for $2,478,818. Following the Form 4 filing with the SEC, Freidin has control over a total of 259,077 common shares of the company, with 259,077 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1699031/000162828025055598/xslF345X05/wk-form4_1764969141.xml

0 · Reply

Market Cap	3.54B
Revenue (ttm)	125.60M
Net Income (ttm)	-2.03B
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,613.86%
Debt to Equity Ratio	0.00

Volume	892,800
Avg Vol	1,160,774
Day's Range	N/A - N/A
Shares Out	38.98M
Stochastic %K	2%
Beta	4.23
Analysts	Sell
Price Target	$105.00